Emollient creams and ointments, antimicrobial-containing
Brand names: Dermol cream, Dermol 500 lotion
These are leave-on emollient creams and ointments that incorporate an antimicrobial (most commonly an antiseptic such as benzalkonium chloride or chlorhexidine) for dry, eczematous skin prone to bacterial colonisation or recurrent infection.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
The emollient base occludes and rehydrates the skin to restore the barrier, while the added antimicrobial reduces surface bacterial load, including staphylococcal colonisation that can drive eczema flares.
Prescribing in practice
- The antiseptic component can cause irritant or allergic contact reactions, so the product should be stopped if the eczema worsens or the skin becomes more inflamed after application.
- These products are for skin prone to infection and are not a substitute for systemic antibiotics in established, spreading skin infection.
- As with all paraffin-based emollients, residue on fabrics and dressings is flammable and fire-safety advice must be given.
Monitoring
No laboratory monitoring is needed; review for local tolerability, signs of contact sensitisation and adequacy of infection control at follow-up.
Counselling the patient
- Apply liberally and frequently to dry skin in the direction of hair growth.
- Stop and seek advice if the skin becomes more red, itchy or sore, which may indicate a reaction to the antiseptic.
- Keep away from naked flames and do not smoke, as the product on skin and fabric is flammable.
Evidence & guidelines
Emollients are a cornerstone of eczema management in NICE guidance, and antimicrobial-containing emollients are used where recurrent bacterial colonisation contributes to flares.
Reference: NICE CKS Eczema; BAD; MHRA Drug Safety Update; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD